Press Releases

Date Title and Summary Additional Formats
Toggle Summary SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
JERSEY CITY, N.J. , April 10, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at the 28 th European Congress of
View HTML
Toggle Summary SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference
JERSEY CITY, N.J. , March 21, 2018 /PRNewswire/ --  SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 17 th Annual Needham Healthcare
View HTML
Toggle Summary SCYNEXIS Presents Data at Superbugs and Superdrugs 2018
Pre-clinical data demonstrates inhibitory activity of SCY-078 against C. auris Two ongoing trials - FURI and CARES - to study oral SCY-078 in patients with refractory fungal infections, including C. auris JERSEY CITY, N.J. , March 20, 2018 /PRNewswire/ -- SCYNEXIS, Inc.
View HTML
Toggle Summary SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update
Robust enrollment continues in Phase 2b VVC trial with top-line data expected in mid-2018 IV SCY-078 program advancing, with liposomal IV formulation to be tested in a Phase 1 study in the third quarter of 2018 Completion of recent $30.0 million equity offering strengthens Company's cash position
View HTML
Toggle Summary SCYNEXIS to Present at the 30th Annual ROTH Conference
JERSEY CITY, N.J. , March 7, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 30 th Annual ROTH Conference at
View HTML
Toggle Summary SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants
JERSEY CITY, N.J. , March 6, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock and warrants. The shares and warrants are being sold at a public offering price of $1.69 per share, the closing price of the stock on March
View HTML
Toggle Summary SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
JERSEY CITY, N.J. , March 5, 2018 /PRNewswire/ --  SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the shares of common stock and warrants in the offering
View HTML
Toggle Summary SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
Data shows synergistic activity and improved outcomes of SCY-078 in combination with isavuconazole Phase 2 trial in invasive aspergillosis expected to initiate in the third quarter of 2018 JERSEY CITY, N.J. , Feb. 1, 2018 /PRNewswire/ --  SCYNEXIS, Inc.
View HTML
Toggle Summary SCYNEXIS to Participate in the Cantor Antibiotics Summit
JERSEY CITY, N.J. , Jan. 11, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in a panel entitled "Novel Ways to
View HTML
Toggle Summary SCYNEXIS Provides Corporate and SCY-078 Pipeline Update
Path Forward Established for IV Program of SCY-078, with Clinical Trials to Initiate in the Third Quarter of 2018 with an Improved IV Formulation Clinical Development of Oral Formulation of SCY-078 Continues to Progress as Planned in Multiple Indications Approvable with an Oral Agent 2018 Strategy
View HTML